The Galien award in the « Rare Diseases » category:
In May 2011, the LFB Group received the Galien Award in the "Rare Diseases" category for its human fibrinogen.
LFB's medicinal products are used to treat diseases that are always serious, and often rare, in hospitalized patients. LFB has renowned expertise in three major therapeutic areas: immunology, intensive care and haemostasis. LFB's commitment to rare diseases is one of the group's long-standing cornerstones of its activity.
Medicinal products for diseases that are always serious and often rare.
More than 60% of LFB's medicinal products are indicated for rare diseases. The LFB Group develops and offers therapeutic solutions for patients with rare or very rare diseases. LFB is one of the only companies in the world to offer a therapeutic solution for coagulation factor XI deficiencies, a fibrinogen, a high purity von Willebrand factor and an Alpha-1 antitrypsin in France. The LFB Group's significant investments in research and development to validate the therapeutic benefits of certain proteins, and in the development of new therapeutic proteins and advanced therapies , are the spearhead of the LFB’s commitment to rare diseases.
Rare diseases: what are they?The term 'rare diseases' describes diseases affecting less than 1 person out of 2,000*. There are between 7,000 and 8,000* rare diseases in the world, 80% of which are of genetic origin. 1 person out of 20* in France has a rare disease.
Haemophilia, Primary Immunodeficiency, dysimmune neuropathy, and a deficiency in certain proteins are just some of the rare diseases that deeply affect the lives of patients.
*French Health Ministry sources.